 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| LB4330 / L&L Biopharma, LB1410 / L&L Biopharma
Enrollment open, Combination therapy, Metastases: TRIGGERCD8: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 9, 2024
P1/2, N=194, Recruiting, Sponsor: L & L biopharma Co., Ltd., Shanghai China
Not yet recruiting --> Recruiting
- |||| LB4330 / L&L Biopharma, LB1410 / L&L Biopharma
New P1/2 trial, Combination therapy, Metastases: TRIGGERCD8: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 21, 2024
P1/2, N=194, Not yet recruiting, Sponsor: L & L biopharma Co., Ltd., Shanghai China
- Bis2 / L&L Biopharma
A phase 1 study of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated (TAA) CD8+T cells in patients with advanced solid tumors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4693;
P1
Dose and efficacy expansion study is ongoing in more PDACs and other solid tumors. In the meantime, Phase I study of LB4330 in combination with PD1/TIM-3 bispecific antibody LB1410 has been initiated in different tumor types as well.
- LB1410 / L&L Biopharma
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors. (Hall A; Poster Bd #: 118) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3040;
P1
LB1410 has manageable safety and shows preliminary efficacy. Additional dose and efficacy expansion study is ongoing in immunotherapy-naive pts with MSS CRC and pts who are resistant to immunotherapy.
- ||| LB1410 / L&L Biopharma
Enrollment open, Metastases: A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma?Keyplus-001? (clinicaltrials.gov) - Dec 29, 2022
P1, N=100, Recruiting, Sponsor: L & L biopharma Co., Ltd., Shanghai China
Additional dose and efficacy expansion study is ongoing in immunotherapy-naive pts with MSS CRC and pts who are resistant to immunotherapy. Not yet recruiting --> Recruiting
- | LB1410 / L&L Biopharma
New P1 trial, Metastases: A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma?Keyplus-001? (clinicaltrials.gov) - May 2, 2022
P1, N=100, Not yet recruiting, Sponsor: L & L biopharma Co., Ltd., Shanghai China
- LB1410 / L&L Biopharma
A bivalent Tim-3/PD-1 bispecific antibody for the treatment of PD-1 antibody resistant or refractory NSCLC. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1826;
Seven cohorts (0.1, 0.3, 1, 3, 6, 10, 15 mg/kg) are planned to be enrolled sequentially in the dose escalation part. In the expansion part, a cohort group of 10 patients is planned for post PD-1 treated NSCLC as the second or third line treatment.